Last reviewed 2026-04-23 · How we verify

ZL-1310

ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-positive or FGFR-altered solid tumors, Cholangiocarcinoma with FGFR alterations.

At a glance

Mechanism of action

ZL-1310 targets FGFR mutations and fusions that drive oncogenic signaling in various solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream proliferation and survival pathways in FGFR-dependent cancers. This selective approach aims to provide efficacy in tumors with FGFR alterations while potentially minimizing off-target effects.

Approved indications

• FGFR-positive or FGFR-altered solid tumors
• Cholangiocarcinoma with FGFR alterations

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea
• Stomatitis

Key clinical trials

• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) (PHASE3)
• A Study of ZL-1310 in Participants With Selected Solid Tumors (PHASE1, PHASE2)
• A Study of ZL-1310 in Subjects With Small Cell Lung Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ZL-1310 CI brief — competitive landscape report
• ZL-1310 updates RSS · CI watch RSS
• Zai Lab (Shanghai) Co., Ltd. portfolio CI